References
- Cho HJ, Bloomberg J, Nichols J. Giant cell arteritis. Dis Mon. 2017;63(3):88–91. doi:10.1016/j.disamonth.2016.10.006.
- Manzo C, Milchert M. Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis: a four-point guidance. Reumatologia. 2018;56:1–2.
- Fraser JA, Weyand CM, Newman NJ, Biousse V. The treatment of giant cell arteritis. Rev Neurol Dis. 2008;5:140–152.
- Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology. 1993;100:550–555.
- Mackie SL, Dejaco C, Appenzeller S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology (Oxford). 2020;59:e1e23.
- Almarzouqi SJ, Morgan ML, Lee AG. Treatment of giant cell arteritis. Curr Opin Ophthalmol. 2015;26:469–475.
- Baig IF, Pascoe AR, Kini A, Lee AG. Giant cell arteritis: early diagnosis is key. Eye Brain. 2019;11:1–12.
- Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315:2442–2458.
- Pioro MH. Primary care vasculitis: polymyalgia rheumatica and giant cell arteritis. Prim Care. 2018;45:305–323.
- Danesh-Meyer HV, Savino PJ. Giant cell arteritis. Curr Opin Ophthalmol. 2007;18(6):443–449. doi:10.1097/ICU.0b013e3282f0b4a9.
- Chan CC, O’Day J. Oral and intravenous steroids in giant cell arteritis. Clin Exp Ophthalmol. 2003;31(3):179–182. doi:10.1046/j.1442-9071.2003.00643.x.
- Winkler A, True D. Giant cell arteritis: 2018 review. Mo Med. 2018;115:468–470.
- Nesher G, Breuer GS. Giant cell arteritis and polymyalgia rheumatica: 2016 update. Rambam Maimonides Med J. 2016;7(4):4. doi:10.5041/RMMJ.10262.
- Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis. 1989;48:662–666.
- V B. What’s hot in the treatment of giant cell arteritis. Paper presented at: North American Neuro-ophthalmology Society Annual Meeting, Snowbird, Utah; 2013.
- Hayreh SS, Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica. 2003;217:239–259.
- Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand. 2002;80:355–367.
- Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261–271.
- Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000;27:1484–1491.
- Cunningham CT, Quan H, Hemmelgarn B, et al. Exploring physician specialist response rates to web-based surveys. BMC Med Res Methodol. 2015;15:32.
- Kellerman SE, Herold J. Physician response to surveys. A review of the literature. Am J Prev Med. 2001;20:61–67.
- Keating NL, Zaslavsky AM, Goldstein J, West DW, Ayanian JZ. Randomized trial of $20 versus $50 incentives to increase physician survey response rates. Med Care. 2008;46:878–881.